Innovation, Preparation of Cephalexin Drug Derivatives and Studying of (Toxicity & Resistance of Infection)
DOI:
https://doi.org/10.61841/k0qmep05Keywords:
Cephalexin, Infection, Contamination, Drug, Toxicity, FormazaneAbstract
The current study developed new drugs and new pharmaceutical derivatives against infection and toxicity via Invention and preparation of medication through various chemical reactions and bio-medical studies to improve its efficiency which involved study of resistance of infection and toxicity effect. The invented Cephalexin derivatives have been prepared through many reactions with many steps, which identified through several techniques represented by (Infrared spectra, carbon and proton magnetic resonance)– spectrophotometric identification methods, then bio- medical studying via several experiment in this field like cytotoxicity, resistance of bacteria.
Downloads
References
[1] Thornhill TS, Levison ME, Johnson WD, Kaye D: In vitro antimicrobial activity and human pharmacology of cephalexin, a new orally absorbed cephalosporin C antibiotic. Appl Microbiol. 1969 Mar; 17(3):457-61.
[2] Sullivan HR, Billings RE, McMahon RE: Metabolism of cephalexin-14C in mice and in rats. J Antibiot (Tokyo). 1969 May; 22(5):195-200.
[3] Gower PE, Dash CH: Cephalexin: human studies of absorption and excretion of a new cephalosporin antibiotic. Br J Pharmacol. 1969 Nov; 37(3):738-47.
[4] Henning C, Kallings LO, Lidman K, Sterner G: Studies of absorption, excretion, antibacterial and clinical effect of cephalexin. Scand J Infect Dis. 1970; 2(2):131-8.
[5] Griffith RS: The pharmacology of cephalexin. Postgrad Med J. 1983; 59 Suppl 5:16-27.
[6] Pfeffer M, Jackson A, Ximenes J, de Menezes JP: Comparative human oral clinical pharmacology of cefadroxil, cephalexin, and cephradine. Antimicrob Agents Chemother. 1977 Feb; 11(2):331-8.
[7] Tanrisever B, Santella PJ: Cefadroxil. A review of its antibacterial, pharmacokinetic and therapeutic properties in comparison with cephalexin and cephradine. Drugs. 1986; 32 Suppl 3:1-16.
[8] Sader HS, Jacobs MR, Fritsche TR: Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagn Microbiol Infect Dis. 2007 Mar; 57(3 Suppl):5S-12S.
[9] Fisher JF, Meroueh SO, Mobashery S: Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev. 2005 Feb; 105(2):395-424.
[10] Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin- binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct; 18(4): 629-37.
[11] Mitsuoka K, Kato Y, Kubo Y, Tsuji A: Functional expression of stereoselective metabolism of cephalexin by exogenous transfection of oligopeptide transporter PEPT1. Drug Metab Dispos. 2007 Mar; 35(3):356-
62. Epub 2006 Dec 1.
[12] Bratlid D, Bergan T: Displacement of albumin-bound antimicrobial agents by bilirubin. Pharmacology.
1976; 14(5):464-72.
[13] Nerli B, Romanini D, Pico G: Structural specificity requirements in the binding of beta lactam antibiotics to human serum albumin. Chem Biol Interact. 1997 May 2; 104(2-3):179-202.
[14] Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: beta- lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21; 275(3):1699-707.
[15] Liang R, Fei YJ, Prasad PD, Ramamoorthy S, Han H, Yang-Feng TL, Hediger MA, Ganapathy V, Leibach FH: Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J Biol Chem. 1995 Mar 24; 270(12):6456-63.
[16] Wenzel U, Gebert I, Weintraut H, Weber WM, Clauss W, Daniel H: Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells. J Pharmacol Exp Ther. 1996 May; 277(2):831-9.
[17] Covitz KM, Amidon GL, Sadee W: Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells. Pharm Res. 1996 Nov; 13(11):1631-4.
[18] Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999 Mar; 88(3):347-50.
[19] Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ: Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther. 1999 Apr; 289 (1):448-54.
[20] Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan; 59(1):17-24.
[21] Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov; 273 (5 Pt 2): F706-11.
[22] Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH: Differential recognition of beta - lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem. 1995 Oct 27; 270 (43): 25672-7.
[23] Tamai I, Nakanishi T, Hayashi K, Terao T, Sai Y, Shiraga T, Miyamoto K, Takeda E, Higashida H, Tsuji A: The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine. J Pharm Pharmacol. 1997 Aug; 49 (8):796-801.
[24] Liu W, Liang R, Ramamoorthy S, Fei YJ, Ganapathy ME, Hediger MA, Ganapathy V, Leibach FH: Molecular cloning of PEPT 2, a new member of the H+/peptide cotransporter family, from human kidney. Biochim Biophys Acta. 1995 May 4; 1235(2):461-6.
[25] Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH: Differential recognition of beta - lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem. 1995 Oct 27; 270 (43): 25672-7.
[26] Terada T, Saito H, Mukai M, Inui K: Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov; 273 (5 Pt 2): F706-11.
[27] Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan; 59 (1):17-24.
[28] Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H: Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine- induced nephrotoxicity: in comparison with rOAT1. Life Sci. 2002 Mar 8; 70(16):1861-74.
[29] Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug; 290(2):672-7.
[30] Uwai Y, Saito H, Inui K: Rat renal organic anion transporter rOAT1 mediates transport of urinary-excreted cephalosporins, but not of biliary-excreted cefoperazone. Drug Metab Pharmacokinet. 2002; 17(2):125-9.
[31] Watanabe S, Tsuda M, Terada T, Katsura T, Inui K: Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug; 334(2):651-6.
[32] Motohashi H, Inui K: Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J. 2013 Apr; 15(2): 581-8.
[33] Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H: Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine- induced nephrotoxicity: in comparison with rOAT1. Life Sci. 2002 Mar 8; 70(16):1861-74.
[34] Thornhill TS, Levison ME, Johnson WD, Kaye D: In vitro antimicrobial activity and human pharmacology of cephalexin, a new orally absorbed cephalosporin C antibiotic. Appl Microbiol. 1969 Mar; 17(3):457-61.
[35] Sullivan HR, Billings RE, McMahon RE: Metabolism of cephalexin-14C in mice and in rats. J Antibiot (Tokyo). 1969 May; 22(5):195-200.
[36] Gower PE, Dash CH: Cephalexin: human studies of absorption and excretion of a new cephalosporin antibiotic. Br J Pharmacol. 1969 Nov; 37(3):738-47.
[37] Henning C, Kallings LO, Lidman K, Sterner G: Studies of absorption, excretion, antibacterial and clinical effect of cephalexin. Scand J Infect Dis. 1970; 2(2):131-8.
[38] Griffith RS: The pharmacology of cephalexin. Postgrad Med J. 1983; 59 Suppl 5:16-27. [PMID:6364086]
[39] Pfeffer M, Jackson A, Ximenes J, de Menezes JP: Comparative human oral clinical pharmacology of cefadroxil, cephalexin, and cephradine. Antimicrob Agents Chemother. 1977 Feb; 11(2):331-8.
[40] Tanrisever B, Santella PJ: Cefadroxil. A review of its antibacterial, pharmacokinetic and therapeutic properties in comparison with cephalexin and cephradine. Drugs. 1986; 32 Suppl 3:1-16.
[41] Sader HS, Jacobs MR, Fritsche TR: Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagn Microbiol Infect Dis. 2007 Mar; 57(3 Suppl):5S-12S. doi: 10.1016/j.diagmicrobio.2006.12.014. Epub 2007 Feb 9. [PMID:17292577]
[42] Fisher JF, Meroueh SO, Mobashery S: Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev. 2005 Feb; 105(2):395-424.
[43] McPherson, Edwin M. (2007). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Burlington: Elsevier.
p. 915. ISBN 9780815518563. Archived from the original on 2017-09-08.
[44] McEvoy, G.K. (ed.). American Hospital Formulary Service — Drug Information 95. Bethesda, MD:
American Society of Hospital Pharmacists, Inc., 1995 (Plus Supplements 1995)., p. 166
[45] Brunton, Laurence L. (2011). "53, Penicillins, Cephalosporins, and Other β-Lactam Antibiotics". Goodman & Gilman's pharmacological basis of therapeutics (12th ed.). New York: McGraw-Hill. ISBN 978- 0071624428.
[46] Wendy Jones (2013). Breastfeeding and Medication. Routledge. p. 227 ISBN 9781136178153. Archived from the original on 2017-09-08.
[47] Hey, Edmund, ed. (2007). Neonatal formulary 5 drug use in pregnancy and the first year of life (5th ed.). Blackwell. p. 67. ISBN 9780470750353. Archived from the original on 2017-09-08.
[48] Ravina, Enrique (2011). The evolution of drug discovery: from traditional medicines to modern drugs (1. Aufl. ed.). Weinheim: Wiley-VCH. p. 267. ISBN 9783527326693. Archived from the original on 2017-09- 08.
[49] Hanlon, Geoffrey; Hodges, Norman (2012). Essential Microbiology for Pharmacy and Pharmaceutical Science. Hoboken: Wiley. p. 140. ISBN 9781118432433. Archived from the original on 2017-09-08.
[50] Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.
[51] Barrio Lera JP, Alvarez AI, Prieto JG (Jun 1991). "Effects of ethanol on the pharmacokinetics of cephalexin and cefadroxil in the rat". Journal of Pharmaceutical Sciences. 80(6): 511–6.
[52] Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao C, Madhusudan Rao Y (2002). "Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers". Drug Metabolism and Drug Interactions. 19(1): 41–8.
[53] B.H.M. Jayakumar, P.N. Balaji, N. Pramod, E. Jajuri, R.N. Rao, Int. J. of Pharmacy & Therapeutics, 3(3), 276-281, (2012) .
[54] Sagheer, O.M., Saour, K.Y., and Ghareeb, M.M. International Journal of Pharmacy and Pharmaceutical Sciences., 5(4) 464-469, (2013).
[55] Nagham Mahmood Aljamali. "Synthesis and Chemical Identification of Macro Compounds of (Thiazol and Imidazol)". Research J. Pharm. and Tech, 2015, 8,1, 78-84.
[56] Mieaad, M., Nagham Mahmood Aljamali, WassanAla, S., Sabreen, A., 2018, "New Azomethine- Azo Heterocyclic Ligands Via Cyclization of Ester ", Research J. Pharm. and Tech. 11, 6.
[57] Mieaad Mohammed, Nagham Mahmood Aljamali, Sabreen Ali Abdalrahman, Wassan Ala Shubber., "Formation of Oxadiazole Derivatives Ligands from Condensation and Imination Reaction with References To Spectral Investigation, Thermal and Microbial Assay"., Biochem. Cell. Arch., 2018, 18, 1, pp. 847-853.
[58] Nagham Mahmood Aljamali. "Synthesis and Biological Study of Hetero (Atoms and Cycles) Compounds", Der Pharma Chemica, 2016, 8, 6, 40-48.
[59] Nagham Mahmood Aljamali.; Intisar Obaid Alfatlawi. "Synthesis of Sulfur Heterocyclic Compounds and Study of Expected Biological Activity", Research J. Pharm. and Tech., 2015, 8, 9, 1225-1242.
[60] Nagham Mahmood Aljamali.; Saher Mahmood Jawd.; Zainab M Jawad.; Intisar, O. Alfatlawi.; 2017, "Inhibition activity of (Azo–acetyl acetone) on bacteria of mouth"., Research Journal of Pharmacy and Technology 10(6):1683-1686.
[61] M. Lindsay Grayson (Editor in Chief) (2 October 2017). Kucers' The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set. CRC Press. pp. 364. ISBN 978-1-4987-4796-7.
[62] Bothara SS, Kadam KR, Mahadik KG (2006). "Antibiotics". Principles of Medicinal Chemistry. 1(14th ed.). Pune: Nirali Prakashan. p. 81. ISBN 8185790043.
[63] Fisher JF, Meroueh SO, Mobashery S (Feb 2005). "Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity". Chemical Reviews. 105(2): 395–424.
[64] Drawz SM, Bonomo RA (Jan 2010). "Three decades of beta-lactamase inhibitors". Clinical Microbiology Reviews 23 (1): 160–201.
[65] Haidareganum, Saher Mahmood Jawd, Nagham Mahmood Aljamali, Benzothiazol derivatives (synthesis, investigation, bio-studying). International Journal of Pharmaceutical Research, Jan-Mar 2019, Vol 11, Issue 1, 1627-1635 .
[66] Linda Skidmore-Roth (16 July 2015). Mosby's Drug Guide for Nursing Students, with 2016 Update.
Elsevier Health Sciences. pp. 181–. ISBN 978-0-323-17297-4.
[67] Nagham Mahmood Aljamali, Rasha Neama H, Aafaq Jaber Alnajem, Ali Jassim Alzuhairi, Afaq Jaber Kadhium, Afaq JK., Studying of (Chemical, Physical, Biological)–Applications of Oxo- Sulfur Derivatives., Journal of Natural Sciences Research., 6, 7, 2016.
[68] Nagham Mahmood Aljamali, Alaa Jawad Kadhim, Jalal Hasan Mohammed, Rajaa Abdul Ameer Ghafil, Alaa JK, Rajaa AAG. Review on Preparation and Applications of Formazan Compounds. International Journal of Thermodynamics and Chemical Kinetics. 2019; 5(2): 23–33p.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
